Literature DB >> 18612763

Relationship between clinical examination, quality of life, disability and depression in CMT patients: Italian multicenter study.

L Padua1, I Aprile, T Cavallaro, I Commodari, D Pareyson, A Quattrone, N Rizzuto, G Vita, P Tonali, A Schenone.   

Abstract

OBJECTIVE: To assess which are the clinical examination tests that are more related to quality of life (QoL), depression, and disability in CMT patients.
DESIGN: Large prospective multicenter study through the use of validated clinical, disability, and QoL measurements. Correlations between clinical pattern and disability/QoL and depression were studied.
SETTING: Departments of Neurology. PATIENTS AND PARTICIPANTS: 211 CMT patients (60% females, mean age 42.5 years).
INTERVENTIONS: None. MEASUREMENTS AND
RESULTS: Sensory function was related to both mental and physical aspects of patient's QoL. Ability to walk on toes and heels was related to physical aspects of QoL/disability but also to bodily pain. Strength of forearm/hand intrinsic muscles was related to disability and physical aspects of QoL.
CONCLUSIONS: Some clinical tests may be better outcome measures than others because they are related to aspects of life highly relevant to the patients. This information may be useful in clinical practice and in clinical trials to infer the patient's QoL.

Entities:  

Mesh:

Year:  2008        PMID: 18612763     DOI: 10.1007/s10072-008-0928-z

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  21 in total

1.  Guidelines for the diagnosis of Charcot-Marie-Tooth disease and related neuropathies. Ad hoc Working Group of the Peripheral Nervous System Study Group, Italian Neurological Society.

Authors:  D Pareyson
Journal:  Ital J Neurol Sci       Date:  1999-08

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A)8-10 April 2005, Naarden, The Netherlands.

Authors:  M M Reilly; P de Jonghe; D Pareyson
Journal:  Neuromuscul Disord       Date:  2006-05-08       Impact factor: 4.296

4.  Improving the sensitivity of the Barthel Index for stroke rehabilitation.

Authors:  S Shah; F Vanclay; B Cooper
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437

5.  Charcot-Marie-Tooth disease type 1A duplication with severe paresis of the proximal lower limb muscles: a long-term follow-up study.

Authors:  J Berciano; E Gallardo; A García; J Infante; I Mateo; O Combarros
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06-20       Impact factor: 10.154

6.  Reliability and validity of the CMT neuropathy score as a measure of disability.

Authors:  M E Shy; J Blake; K Krajewski; D R Fuerst; M Laura; A F Hahn; J Li; R A Lewis; M Reilly
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

Review 7.  The tools of disability outcomes research functional status measures.

Authors:  M E Cohen; R J Marino
Journal:  Arch Phys Med Rehabil       Date:  2000-12       Impact factor: 3.966

8.  The phenotypic manifestations of chromosome 17p11.2 duplication.

Authors:  P K Thomas; W Marques; M B Davis; M G Sweeney; R H King; J L Bradley; J R Muddle; J Tyson; S Malcolm; A E Harding
Journal:  Brain       Date:  1997-03       Impact factor: 13.501

Review 9.  Diagnosis of hereditary neuropathies in adult patients.

Authors:  Davide Pareyson
Journal:  J Neurol       Date:  2003-02       Impact factor: 4.849

10.  Motor and functional recovery after stroke: accuracy of physical therapists' predictions.

Authors:  N Korner-Bitensky; N Mayo; R Cabot; R Becker; H Coopersmith
Journal:  Arch Phys Med Rehabil       Date:  1989-02       Impact factor: 3.966

View more
  9 in total

1.  Efficacy of focal mechanic vibration treatment on balance in Charcot-Marie-Tooth 1A disease: a pilot study.

Authors:  Costanza Pazzaglia; F Camerota; M Germanotta; E Di Sipio; C Celletti; L Padua
Journal:  J Neurol       Date:  2016-05-13       Impact factor: 4.849

2.  An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.

Authors:  Shahram Attarian; Jean-Michel Vallat; Laurent Magy; Benoît Funalot; Pierre-Marie Gonnaud; Arnaud Lacour; Yann Péréon; Odile Dubourg; Jean Pouget; Joëlle Micallef; Jérôme Franques; Marie-Noëlle Lefebvre; Karima Ghorab; Mahmoud Al-Moussawi; Vincent Tiffreau; Marguerite Preudhomme; Armelle Magot; Laurène Leclair-Visonneau; Tanya Stojkovic; Laura Bossi; Philippe Lehert; Walter Gilbert; Viviane Bertrand; Jonas Mandel; Aude Milet; Rodolphe Hajj; Lamia Boudiaf; Catherine Scart-Grès; Serguei Nabirotchkin; Mickael Guedj; Ilya Chumakov; Daniel Cohen
Journal:  Orphanet J Rare Dis       Date:  2014-12-18       Impact factor: 4.123

Review 3.  Charcot-Marie-Tooth disease, psychiatric indicators and quality of life: a systematic review.

Authors:  Joana L C Cordeiro; Wilson Marques; Jaime E C Hallak; Flávia L Osório
Journal:  ASN Neuro       Date:  2014-05-27       Impact factor: 4.146

Review 4.  Management of Charcot-Marie-Tooth disease: improving long-term care with a multidisciplinary approach.

Authors:  Donald McCorquodale; Evan M Pucillo; Nicholas E Johnson
Journal:  J Multidiscip Healthc       Date:  2016-01-19

5.  Physical and Mental Aspects of Quality of Life in Patients With Charcot-Marie-Tooth Disease Type 1A.

Authors:  Vukan Ivanovic; Bogdan Bjelica; Aleksa Palibrk; Marija Brankovic; Ivo Bozovic; Ivana Basta; Andrija Savic; Vidosava Rakocevic Stojanovic; Aleksandra Kacar
Journal:  Front Neurol       Date:  2022-03-16       Impact factor: 4.003

6.  Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT): A Protocol to Address Clinical Trial Readiness in CMT1A.

Authors:  Katy Eichinger; Janet E Sowden; Joshua Burns; Michael P McDermott; Jeffrey Krischer; John Thornton; Davide Pareyson; Steven S Scherer; Michael E Shy; Mary M Reilly; David N Herrmann
Journal:  Front Neurol       Date:  2022-06-27       Impact factor: 4.086

7.  Anxiety and depression in Charcot-Marie-Tooth disease: data from the Italian CMT national registry.

Authors:  Marta Bellofatto; Alessandro Bertini; Irene Tramacere; Fiore Manganelli; Gian Maria Fabrizi; Angelo Schenone; Lucio Santoro; Tiziana Cavallaro; Marina Grandis; Stefano C Previtali; Isabella Allegri; Luca Padua; Costanza Pazzaglia; Daniela Calabrese; Paola Saveri; Aldo Quattrone; Paola Valentino; Stefano Tozza; Luca Gentile; Massimo Russo; Anna Mazzeo; Giuseppe Vita; Sylvie Piacentini; Chiara Pisciotta; Davide Pareyson
Journal:  J Neurol       Date:  2022-09-16       Impact factor: 6.682

8.  Postural stabilization and balance assessment in Charcot-Marie-Tooth 1A subjects.

Authors:  T Lencioni; M Rabuffetti; G Piscosquito; D Pareyson; A Aiello; E Di Sipio; L Padua; F Stra; M Ferrarin
Journal:  Gait Posture       Date:  2014-07-15       Impact factor: 2.840

Review 9.  How to manage with telemedicine people with neuromuscular diseases?

Authors:  Fiore Manganelli; Luigi Lavorgna; Emanuele Spina; Francesca Trojsi; Stefano Tozza; Aniello Iovino; Rosa Iodice; Carla Passaniti; Gianmarco Abbadessa; Simona Bonavita; Letizia Leocani; Gioacchino Tedeschi
Journal:  Neurol Sci       Date:  2021-06-25       Impact factor: 3.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.